TP10-Dopamine Conjugate as a Potential Therapeutic Agent in the Treatment of Parkinson’s Disease

Parkinson’s disease (PD) is a common progressive neurodegenerative disorder for which the current treatment is not fully satisfactory. One of the major drawbacks of current PD therapy is poor penetration of drugs across the blood-brain barrier (BBB). In recent years, cell-penetrating peptides (CPPs)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bioconjugate chemistry 2019-03, Vol.30 (3), p.760-774
Hauptverfasser:	Rusiecka, Izabela, Ruczyński, Jarosław, Kozłowska, Agnieszka, Backtrog, Ewelina, Mucha, Piotr, Kocić, Ivan, Rekowski, Piotr
Format:	Artikel
Sprache:	eng
Schlagworte:	Animal models Animals Antiparkinson Agents - therapeutic use Basal ganglia Blood-brain barrier Brain - metabolism Catechol Catechol O-methyltransferase Cell membranes Cell-Penetrating Peptides - chemistry Cell-Penetrating Peptides - metabolism Central nervous system Central nervous system diseases Chemical compounds Conjugates Conjugation Dihydroxyphenylalanine Dopamine Dopamine - chemistry Dopamine - metabolism Dopamine D1 receptors Dopamine D2 receptors Drug carriers Drug delivery Levodopa Male Medical treatment Membranes Methylation Methyltransferase Mice Mice, Inbred BALB C Movement disorders MPTP Neurodegenerative diseases Parkinson Disease - drug therapy Parkinson Disease - metabolism Parkinson's disease Peptides Pharmacology Receptors Receptors, Dopamine D1 - metabolism Receptors, Dopamine D2 - metabolism Recombinant Fusion Proteins - chemistry Recombinant Fusion Proteins - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!